Shaping a new class of GPCR therapeutics.

The name Skape Bio draws from the Old Norse skapa — to create, to shape. It reflects our Danish origins and our mission: to build proteins from scratch.

Our miniproteins occupy a new therapeutic class between small molecules and biologics, reaching targets that have long resisted both.

Our Team

We’ve assembled a team of protein designers, structural biologists, and GPCR pharmacologists working to solve the bottlenecks that have stalled GPCR drug discovery for decades.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Amrita Nallathambi, PhD

Protein Designer

Ana-Maria Bratovianu, MSc

Scientist & Co-Founder

Areso Ahmadsay, MSc

Admin & Operations

Bryan Roth, MD, PhD

Bryan White

Board Member & Co-Founder

Chris Norn, PhD

CEO / Co-Founder / Board Member

Chris Tate, PhD

David Baker, PhD

Board Observer & Co-Founder

David Feldman, PhD

David Kim, PhD

David Younger, PhD

Dima Borisevich, PhD

Director of Data Engineering

Edin Muratspahic, PhD

Emil Hertz, PhD

Head of Discovery

Henrik Stage

Board Member & Co-Founder

Jakob Staun Pallesen

Board Observer

Jan Voss, PhD

Lead Pharmacologist

Lance Stewart, PhD, MBA

Board Chair & Co-Founder

Mads Jeppesen, PhD

Protein Designer

Malcolm Weir, PhD

Marina Mohr, PhD

Director of Operations & Strategy

Mark Gurney, PhD, MBA

Matt Barnes, PhD

Chief Scientific Officer

Mette Rosenkilde, PhD

Paula Rivera Sánchez, MSc

Scientist & Co-Founder

Pia Peceli, MSc

Research Assistant

Robert Blazej

Board Observer

Samuel Pine, PhD

VP of DMPK